'Why we do What we do in Cardiology'

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

Listen Later

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

  • Mavacamten: Class 1 recommendation for symptomatic obstructive HCM.
  • Exercise: Now allows for "vigorous" activity; competitive level still limited.
  • Pediatric Section: Separate guidelines with new risk-prediction tools.
  • Atrial Fibrillation: Enhanced monitoring is recommended.
  • Future Research: Needed on nonobstructive HCM and cardiac myosin inhibitors' long-term effects.

    • ...more
    View all episodesView all episodes
    Download on the App Store
    'Why we do What we do in Cardiology'By Bishnu Subedi

    More shows like 'Why we do What we do in Cardiology'

    View all
    This Week in Cardiology by Medscape

    This Week in Cardiology

    902 Listeners

    Core IM | Internal Medicine Podcast by Core IM Team

    Core IM | Internal Medicine Podcast

    1,142 Listeners